Heart FailureRelation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION)
Section snippets
Methods
HF-ACTION was a trial of exercise training versus usual care in 2,331 patients with EF ≤35% and New York Heart Association (NYHA) class II to IV symptoms despite optimal HF therapy for at least 6 weeks.9 Patients with major co-morbidities that could interfere with exercise training, including exercise-limiting AP, were excluded from HF-ACTION. In patients randomized to exercise training, the protocol included 36 supervised exercise sessions followed by home-based training for an additional
Results
From the HF-ACTION cohort, 406 of 2,331 patients (17%) had AP at baseline and worse NYHA class and depression but similar proBNP level compared with those without baseline AP (Table 1). Baseline exercise parameters were similar by AP status, but patients with AP had worse HRQoL scores (Table 2). Adherence rates to the exercise intervention at 3 months in patients with and without baseline AP were 51 of 186 (27%) versus 205 of 828 (25%), respectively (p = 0.45).
Baseline AP was associated with a
Discussion
In this study, ambulatory patients with HFrEF with AP had a 25% increased risk for all-cause hospitalization but no significant differences in all-cause or CV mortality over a follow-up period of 2.5 years. Depression was common (21%) in the overall HF-ACTION population, but patients with AP had increased prevalence and severity of depression along with worse HRQoL. Exercise training conferred similar benefits to patients with versus without AP. Several factors may account for the observed
Disclosures
Kishan S. Parikh, MD: none. Adrian Coles, PhD: none. Phillip J. Schulte: none. Robert Mentz, MD: NIH (U10HL110312), Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Otsuka, and ResMed; honoraria from HeartWare, Janssen, Luitpold Pharmaceuticals, Novartis, ResMed, and Thoratec; and has served on an advisory board for Luitpold Pharmaceuticals, Inc. William E. Kraus: none. Steven J. Keteyian, PhD: none. Jerome L. Fleg, MD: none. Ileana L. Piña, MD, MPH: none. Mona
References (22)
- et al.
A standardized definition of ischemic cardiomyopathy for use in clinical research
J Am Coll Cardiol
(2002) - et al.
Comparison of clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease)
Am J Cardiol
(2012) - et al.
Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease)
J Am Coll Cardiol
(2014) - et al.
Quality of life and time trade-off utility measures in patients with coronary artery disease
Am Heart J
(2003) - et al.
Characteristics of a contemporary population with angina pectoris. TIDES investigators
Am J Cardiol
(1994) - et al.
Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH
J Am Coll Cardiol
(2015) - et al.
Temporal trends and factors associated with cardiac rehabilitation referral among patients hospitalized with heart failure: findings from Get with the guidelines-heart failure Registry
J Am Coll Cardiol
(2015) - et al.
Limitations of Canadian cardiovascular society classification of angina pectoris
Am J Cardiol
(1994) - et al.
Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events
Eur J Heart Fail
(2014) - et al.
Stable angina pectoris: antianginal therapies and future directions
Nat Rev Cardiol
(2012)
Impact of self-management interventions on stable angina symptoms and health-related quality of life: a meta-analysis
BMC Cardiovasc Disord
Cited by (12)
Exercise-based cardiac rehabilitation for adults with heart failure
2024, Cochrane Database of Systematic ReviewsThe validity and reliability of the Turkish version of the Seattle Angina Questionnaire
2020, Turk Kardiyoloji Dernegi ArsiviPotentially inappropriate medications in elderly patients with heart failure: Beers Criteria-based study
2020, International Journal of Pharmacy PracticeCritical factors in quality of life: A qualitative explorations into the experiences of Malaysian with heart failure
2020, Malaysian Journal of Medicine and Health SciencesHealth-related quality of life and its associated factors among patients with angina in Jordan
2020, Quality of Life Research
The contents of this manuscript are solely the responsibility of the authors and do not necessarily reflect the views of the National Institutes of Health or the Department of Health and Human Services.
Funding was provided by Gilead Sciences. Work for the analysis was supported by grants U10HL110312 (Dr. Mentz) and 5T32GM086330-05 (Dr. Parikh) from NIH (Bethesda, MD). The HF-ACTION trial was funded by grants HL063747 and HL093374 from the National Heart, Lung, and Blood Institute (Bethesda, MD).
See page 1215 for disclosure information.